UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000004322 |
|---|---|
| Receipt number | R000005181 |
| Scientific Title | A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in methicillin-resistant staphylococcus aureus (MRSA) infection; an open-label, non-randomized study |
| Date of disclosure of the study information | 2010/10/04 |
| Last modified on | 2023/05/30 13:11:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in methicillin-resistant staphylococcus aureus (MRSA) infection; an open-label, non-randomized study
Acronym
A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in MRSA infection
Scientific Title
A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in methicillin-resistant staphylococcus aureus (MRSA) infection; an open-label, non-randomized study
Scientific Title:Acronym
A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in MRSA infection
Region
| Japan |
Condition
Condition
MRSA infection
Classification by specialty
| Infectious disease | Orthopedics | Intensive care medicine |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate a relationship between linezolid-induced myelosuppression and serum linezolid concentrations, blood sample are assayed after administration of linezolid intravenously or orally in MRSA infections.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
A relationship between linezolid-induced myelosuppression and serum linezolid concentrations
Key secondary outcomes
Blood concentration-time profile of major metabolites in patients
Urinary excretion amounts of linezolid and major metabolites in patients
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
All patients receive a dose of 600 mg linezolid every 12h orally or intravenously, and their blood samples are assayed.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) age, 20 years or higher
2) MRSA infections, including suspicions
3) Inpatients and outpatients in our hospital
4) Prescribed blood sampling were available
5) gave their or their relatives' written informed consent
Key exclusion criteria
1) history of hypersensitivity to ZYVOX
2) pregnancy, parturition or lactation
3) other situation that doctor decides
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshimichi Sai |
Organization
Kanazawa University Hospital
Division name
Department of Pharmacy
Zip code
Address
13-1 Takara-machi, Kanazawa 920-8641
TEL
076-265-2000
sai-ys@staff.kanazawa-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yoshimichi Sai |
Organization
Kanazawa University Hospital
Division name
Department of Pharmacy
Zip code
Address
13-1 Takara-machi, Kanazawa 920-8641
TEL
076-265-2046
Homepage URL
sai-ys@staff.kanazawa-u.ac.jp
Sponsor or person
Institute
Kanazawa University Hospital
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 10 | Month | 04 | Day |
Related information
URL releasing protocol
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000005181
Publication of results
Published
Result
URL related to results and publications
https://pubmed.ncbi.nlm.nih.gov/30459957/
Number of participants that the trial has enrolled
28
Results
Our clinical study indicated that multiple doses of rifampicin (RFP) reduced the dose-normalized trough concentration of linezolid (LZD) at the first assessment day by an average of 65%.
Results date posted
| 2023 | Year | 05 | Month | 30 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
All participants, who were adults being treated with oral LZD 600 mg every 12 h.
Participant flow
All participants, who were adults being treated with oral LZD 600 mg every 12 h.
The present study included 7 patients in the LZD group and 3 patients in the LZD/RFP group.
Adverse events
none
Outcome measures
sex, age, body weight, estimated glomerular filtration rate, C-reactive protein, platelet count, Hb concentration, duration of LZD therapy, total dosage, daily dose,
trough concentration of LZD at the first assessment day during LZD therapy, number of instances of TDM, concomitant drugs received during LZD therapy and success rate
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2010 | Year | 09 | Month | 09 | Day |
Date of IRB
| 2010 | Year | 09 | Month | 09 | Day |
Anticipated trial start date
| 2010 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2013 | Year | 12 | Month | 19 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 10 | Month | 04 | Day |
Last modified on
| 2023 | Year | 05 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005181
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
